One disease, known as Malignant Pleural Effusion (MPE), is present in 15% of cancer patients. Finding the right treatment is crucial given the short overall survival rate. It should be determined whether cases require a more vigorous course of treatment in addition to palliating secondary symptoms brought on by MPE. The aim of the study was to assess how well LENT and clinical PROMISE scores predicted survival in MPE patients.
